Phenytoin Testing Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Reagents & Kits and Equipment) By Sample Type (Blood, Saliva, and Others), By Technology (Enzyme Linked Immunosorbent Assay (ELISA), Latex Enhanced Immunoturbidimetry, and Others), By End User (Hospitals & Clinics, Clinical Laboratories, and Others), and Regional Forecast, 2025-2032

Phenytoin is an anti-epileptic drug used to treat various seizure disorders, also known as epilepsy. The phenytoin test is used to monitor the drug's therapeutic window. It is essential to monitor phenytoin levels since even low concentrations can cause seizures in susceptible individuals, and large concentrations can cause toxicity. This test is used to determine the concentration of phenytoin in the blood.

The growing incidence of epileptic seizures worldwide is an important factor contributing to the growth of the phenytoin testing market.

• For instance, according to data published by World Health Organization (WHO) in February 2023, people of all ages are susceptible to epilepsy, the most prevalent chronic brain illness. Epilepsy is one of the most prominent neurological disorders worldwide, affecting around 50 million people.

Impact of COVID-19 on the Phenytoin Testing Market

The phenytoin market experienced a slightly positive impact in 2020 by the COVID-19 pandemic. During the pandemic, epilepsy was induced by COVID-19 infection.

• For instance, in November 2020, according to data published by NIH, epilepsy was induced by COVID-19 through five different mechanisms.

During COVID-19, patients with epilepsy on phenytoin therapy showed severe adverse reactions; thus, measuring the therapeutic levels of phenytoin in the blood is necessary to avoid health hazards, which increases the number of phenytoin testing.

• For instance, according to an article published in June 2020, there are chances of interaction of epileptic patients with COVID-19 treatments.

Key Insights

The following key insights will be covered in the report:

• Prevalence of Epilepsy - By Key Countries/Regions, 2022.

• New Product Launches, By Key Players.
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.).
• Impact of COVID-19 on the Phenytoin Testing Market.

Analysis by Sample Type

Based on sample type, the blood sample segment accounted for a significant proportion of the global Phenytoin testing market. This can be attributed to the high availability of test kits that use blood samples for the detection of phenytoin. Diagnostic laboratories also provide phenytoin testing based on blood samples.

• For instance, Laboratory Corporation of America Holdings (LabCorp) offers phenytoin testing using serum or plasma.

Furthermore, increasing the focus of operating players in the development of new products for phenytoin testing is also expected to supplement the segment growth.

Regional Analysis 

To gain extensive insights into the market, Download for Customization

North America is anticipated to dominate the global phenytoin testing market in 2022. The key factors contributing to the regional dominance include the growing prevalence of epileptic disorders in the region, the presence of well-established players & their initiatives to expand their product offerings in the region, and the well-developed healthcare infrastructure.

• In March 2023, according to the data published by National Centre for Chronic Disease Prevention and Health Promotion, around 3.4 million people were affected with epilepsy in the U.S., of which 4,70,000 were children and 3 million were adults.

Key Players Covered

The report will include the profiles of the key players such as Abbott, Danaher, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Neogen Corporation, SEKISUI MEDICAL CO., LTD, Randox Laboratories Ltd, Quest Diagnostics Inc., ARUP Laboratories, and others.

Report Scope & Segmentation

Key Industry Developments

• June 2022: Pfizer announced the submission of a New Drug Application of drug PAXLOVID to the U.S. FDA. Phenytoin, a potent CYP3A inducer, has been contraindicated for treatment with PAXLOVID by the company, due to chances of severe side effects which results in increased demand for phenytoin testing.
• April 2014: Quest Diagnostics unveiled a series of new testing options from its Athena Diagnostics specialty neurology division that will help doctors more accurately and rapidly determine the origin of different types of epilepsy in both adults and children. The new laboratory-developed tests based on neuroimmunological testing and next-generation gene sequencing include the first multi-analyte test panel to analyze five antibodies linked to autoimmune epilepsy, responsible for up to 10% of epilepsy cases.